On August 31, 2026 Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, reported that the Company will participate in the following upcoming investor conferences:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citi 2026 Biopharma Back to School Conference
Date and Time: September 10, 2026 at 1 p.m. ET
Format: Fireside Chat
Location: New York, NY

Morgan Stanley 24th Annual Global Healthcare Conference
Date and Time: September 15, 2026 at 1:50 p.m. ET
Format: Fireside Chat
Location: New York, NY

H.C. Wainwright 28th Annual Global Investment Conference
Date and Time: September 16, 2026 at 9:30 a.m. ET
Format: Fireside Chat
Location: New York, NY

Live webcasts and recordings of these presentations will be available, as permitted by the event host, in the Events and Presentations section of Olema’s investor relations website at ir.olema.com.

(Press release, Olema Oncology, AUG 31, 2026, View Source [SID1234670474])

On August 31, 2026 Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, reported that it will present data from multiple clinical programs, including an oral presentation of initial data from the RESTORE-PV trial of DISC-3405 in patients with polycythemia vera (PV), at the SOHO Annual Meeting, which will be held in Houston, Texas on September 9-12, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are excited to share the first clinical data from our Phase 2 study of DISC-3405 in polycythemia vera at the upcoming SOHO conference," said John Quisel, J.D., Ph.D., President and Chief Executive Officer of Disc Medicine. "Together with our myelofibrosis posters, these presentations highlight the continued progress of our clinical-stage portfolio of therapies targeting myeloproliferative neoplasms and our commitment to addressing significant unmet needs for patients with these diseases."

The oral presentation of data from the Phase 2 RESTORE-PV study in patients with polycythemia vera will share baseline and safety data for N=40 patients from Cohorts A and B, as well as PK, PD, and other efficacy endpoints for the N=20 patients from Cohort A.

DISC-0974 and DISC-3405 are investigational agents and are not approved for use as therapies in any jurisdiction worldwide.

Details of Presentations and Abstracts:

DISC-3405 Oral Presentation:

Abstract Title: Restore-PV: A Phase 2 Open-Label Study Evaluating the Safety and Efficacy of the Anti-TMPRSS6 Monoclonal Antibody DISC-3405 in Participants with Polycythemia Vera
Session Title: Session IV: Myeloproliferative Neoplasms
Oral Presentation Session Details: Thursday, September 10th 9:55 am CT / 10:55 am ET
Presenting Author: Naseema Gangat, M.B.B.S.

These data will also be shared as part of the poster presentation as poster number MPN-099 on Wednesday, September 9th at 6:25 pm CT / 7:25 pm ET.

DISC-0974 Abstracts:

Abstract Title: RALLY-MF: Initial Efficacy of a Phase 2 Study of DISC-0974, an Anti-Hemojuvelin Antibody, to Treat Anemia in Myelofibrosis
Session Title: Session IV: Myeloproliferative Neoplasms
Oral Presentation Session Details: Thursday, September 10th 9:45 am CT / 10:45 am ET
Presenting Author: Naseema Gangat, M.B.B.S.

These data, with a data cutoff date of April 27, 2026, will also be shared as part of the poster presentation as poster number MPN-120 on Wednesday, September 9th at 6:25 pm CT / 7:25 pm ET.

Poster Number: MPN-809
Abstract Title: Characterizing the Humanistic Burden of Anemia Associated With Myelofibrosis Through Patient-Reported Outcomes: Findings from a Systematic Literature Review
Session Details: Wednesday, September 9th at 6:25 pm CT / 7:25 pm ET
Author: Chelsea Norregaard, PhD

(Press release, Disc Medicine, AUG 31, 2026, View Source [SID1234670473])

On August 31, 2026 PMV Pharmaceuticals, Inc. ("PMV Pharma" or the "Company"; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, reported the pricing of an underwritten public offering consisting of (i) 22,055,000 shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase an aggregate of up to 19,900,000 shares of its common stock, and (ii) accompanying warrants to purchase an aggregate of 41,955,000 shares of common stock. The common stock and pre-funded warrants are being sold in combination with an accompanying warrant to purchase one share of common stock for each share of common stock or pre-funded warrant sold. The accompanying warrants have an initial exercise price of $1.21 per share, subject to adjustment following a specified regulatory milestone, are immediately exercisable from the date of issuance and will expire five years from the date of issuance.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The combined public offering price of each share of common stock and accompanying warrant is $1.21. The combined public offering price of each pre-funded warrant and accompanying warrant is $1.20999, representing the purchase price less an exercise price of $0.00001 per pre-funded warrant.

All of the securities being sold in the offering are being sold by PMV Pharma. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, and any exercise of the warrants, are expected to be approximately $50.8 million.

TD Cowen is acting as the sole book-running manager for the offering. The offering is expected to close on or about September 2, 2026, subject to customary closing conditions.

The securities are being offered by PMV Pharma pursuant to a shelf registration statement on Form S-3 (Registration No. 333-283349), as filed with the U.S. Securities and Exchange Commission ("SEC") on November 20, 2024 and declared effective by the SEC on November 27, 2024. A preliminary prospectus supplement relating to and describing the terms of the offering was filed with the SEC on August 31, 2026. The final prospectus supplement and accompanying prospectus relating to and describing the terms of the offering will be filed with the SEC and may also be obtained, when available, from: TD Securities (USA) LLC, by mail at c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

(Press release, PMV Pharma, AUG 31, 2026, View Source [SID1234670472])

On August 31, 2026 BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, reported a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne’s longstanding commitment to patient access and investment in research and scientific innovation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

John V. Oyler, Co-Founder, Chairman and CEO, BeOne Medicines, said:
"At BeOne, we believe every patient should benefit from innovative cancer therapies. We appreciate the Trump Administration’s commitment to advancing solutions that broaden access and scientific progress for American patients. This agreement reflects our purpose to reach more patients as we expand our U.S. investment in additional research, development, and manufacturing to deliver breakthrough cancer treatments worldwide."

Improved access to oncology medicines for patients
This announcement reflects BeOne’s participation in the GENEROUS (GENErating cost Reductions fOr U.S. Medicaid) Model and the company’s commitment to pricing future FDA-approved products in line with other key developed markets.

Increased manufacturing and investment
Through continued investments in U.S. manufacturing, BeOne is enhancing supply continuity and manufacturing flexibility while supporting patient access to innovative medicines.

BeOne entered into an onshoring agreement with the U.S. government, securing an exemption from Section 232 pharmaceutical tariffs that recognizes the company’s significant and ongoing investments in US. manufacturing.
The company recently announced a $300 million onshoring investment in its flagship clinical and commercial-stage manufacturing and research and development facility in Hopewell, NJ, bringing total U.S. manufacturing investment to more than $1 billion. The expansion will add small-molecule manufacturing capacity, create approximately 120 full-time jobs and enhance BeOne’s ability to manufacture medicines in the states and advance its oncology pipeline of more than 35 clinical- and commercial-stage assets.
The U.S. is an important hub for BeOne’s scientific, clinical and manufacturing operations. BeOne employs more than 2,000 U.S. colleagues within a global team of more than 12,000 across six continents. In 2025, the company generated nearly $2 billion in direct U.S. economic impact and invested $1 billion in U.S. research and development. BeOne is also advancing one of oncology’s broadest pipelines through 93 clinical trials at approximately 1,100 sites across 45 states and one territory, supported by more than 650 investigators.

(Press release, BeOne Medicines, AUG 31, 2026, View Source [SID1234670471])

On August 31, 2026 BostonGene, developer of the leading AI model for tumor and immune biology, reported that two abstracts have been accepted for poster presentation at Society of Hematologic Oncology (SOHO) 2026 Annual Meeting, taking place September 9 – 12 in Houston, Texas. The 14th Annual Meeting will bring together thousands of global experts to showcase practice-changing breakthroughs and practical clinical applications in blood cancer treatment.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

At SOHO 2026, BostonGene will highlight advanced molecular stratification frameworks designed to unlock actionable insights from complex multimodal datasets. These studies provide biopharma partners with robust translational tools to optimize patient selection, guide treatment sequencing, and accelerate precision oncology pipelines across B-cell lymphomas and multiple myeloma.

Details about the abstracts selected for presentation can be found below:

Poster presentations
Poster number: MM-442
Title: An Actionability Score for BCMA-, GPRC5D-, and CD38-targeted therapy selection in multiple myeloma
Date & time: Wednesday, September 9 | 6:25 – 7:55 PM EDT
Location: Hall B3, Level 3 – George R. Brown Convention Center
Speaker: Tamara Laskowski, PhD, BostonGene

BostonGene introduced an NGS-based Actionability Score (AS) framework that integrates target gene expression, resistance factors, and tumor microenvironment signatures to predict response and guide treatment selection across key immunotherapies targets (BCMA, GPRC5D, and CD38) in multiple myeloma. Applied across multiple myeloma cohorts, the AS framework identified distinct actionable profiles and potential resistance mechanisms, offering biopharma a predictive tool to refine clinical trial design and optimize treatment sequencing.

Poster number: ABCL-443
Title: Cross-disease stratification by genetic classifier Lymphly reveals shared molecular programs across B-cell malignancies
Date & time: Wednesday, September 9 | 6:25 – 7:55 PM EDT
Location: Hall B3, Level 3 – George R. Brown Convention Center
Speaker: Mark Meerson, MSc, BostonGene

BostonGene evaluated its interpretable, rule-based genetic classifier, Lymphly, across more than 6,500 DLBCL and non-DLBCL B-cell lymphoma samples. The study demonstrates that Lymphly uncovers shared molecular biology across diverse B-cell diagnoses, maintains superior subtype assignment preservation compared to legacy classifiers even with limited targeted panel data, and retains independent prognostic value, establishing a robust framework for cross-disease stratification and biomarker-driven trial design.

(Press release, BostonGene, AUG 31, 2026, View Source [SID1234670470])